Company Overview and News

Stanley Black & Decker: Buy Its Stock Or Buy Its Tools?

2018-09-05 seekingalpha
Stanley Black & Decker (SWK) has been around for a long time. So long, in fact, that the company has been distributing dividends for over 140 years. It has recently obtained the holy title of Dividend King, increasing its dividend for more than 50 consecutive years. Consumer’s confidence in products manufactured by Stanley Black & Decker keeps growing, providing a stable long run growth. SWK is a robust player in its industry, which enabled the company to recently acquire IES Attachments business for its fastening division.

Techtronic Industries Co Ltd (TTNDY) CEO Joseph Galli on Q2 2018 Results - Earnings Call Transcript

2018-08-17 seekingalpha
Techtronic Industries Co Ltd (OTCPK:TTNDY) Q2 2018 Earnings Conference Call August 15, 2018 8:00 AM ET

Techtronic Industries Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Techtronic Industries Ltd. ADR in conjunction with their 2018 Q2 earnings call.

Lexington May Be Down, But Certainly Not Out

2018-05-28 seekingalpha
LXP’s dividend is safe, but don’t expect to see a lot of growth this year or next.

Hong Kong company earnings results spur buying of own company shares by directors

2018-03-25 scmp
Buying of shares in their own companies by Hong Kong directors rebounded sharply in the March 19 to March 23 week, according to filings to the stock exchange, while selling rose for a third straight week.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...